Product
161Tb-DOTA-LM3
1 clinical trial
2 indications
Indication
Neuroendocrine NeoplasiaClinical trial
Combined Beta- Plus Auger Electron Therapy Using a Novel Somatostatin Receptor Subtype 2 Antagonist Labelled With Terbium-161 (161Tb-DOTA-LM3): Beta Plus StudyStatus: Recruiting, Estimated PCD: 2025-12-01